프로태고니스트 테라퓨틱스(PTGX)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $142.50 (-0.84%), 시가총액 $6.66B, 52주 최저~최고 $43.77 ~ $105.98.
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development c
프로태고니스트 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
프로태고니스트 테라퓨틱스의 현재 주가는 $142.50 (-0.84%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
프로태고니스트 테라퓨틱스의 시가총액은 약 $6.66B입니다.
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of ad